{"id":"NCT01840605","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis","officialTitle":"A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis (Ketotifen Fumarate-controlled, Double-blind, Comparative Study)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-03","primaryCompletion":"2013-11","completion":"2013-11","firstPosted":"2013-04-26","resultsPosted":"2015-10-16","lastUpdate":"2018-05-25"},"enrollment":303,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Dermatitis","Atopic"],"interventions":[{"type":"DRUG","name":"Bepotastine besilate","otherNames":["TALION 5mg tablets"]},{"type":"DRUG","name":"ketotifen fumarate","otherNames":["ketotifen fumarate dry syrup"]}],"arms":[{"label":"TAU-284","type":"EXPERIMENTAL"},{"label":"ketotifen fumarate","type":"ACTIVE_COMPARATOR"}],"summary":"The objective of this study is to verify the non-inferiority of TAU-284 to ketotifen fumarate dry syrup in the change in the severity of pruritus after the treatment period.","primaryOutcome":{"measure":"Change From Baseline in Pruritus Score","timeFrame":"Baseline and 2 weeks","effectByArm":[{"arm":"TAU-284","deltaMin":-0.669,"sd":0.058},{"arm":"Ketotifen Fumarate","deltaMin":-0.638,"sd":0.058}],"pValues":[]},"eligibility":{"minAge":"7 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":10},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":151},"commonTop":["Nasopharyngitis","Somnolence"]}}